Skip to content

ADMA Biologics

US · ADMA #2705 by market cap Listed 1970
13.17 -0.17 -1.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.92 In line with history 51st percentile
5-year average 8.78 · #428 of 514 in Biotechnology
P/E ratio 17.77 Expensive vs history 69th percentile
5-year average -18.60 · forward 16.51 · #45 of 77 in Biotechnology
P/S ratio 5.85 In line with history 58th percentile
5-year average 6.59 · forward 5.16 · #126 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
ADMA Biologics (ADMA) 2.92B 17.10 6.66 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value13.05 Economic moatNone UncertaintyHigh

Trading 0.9% above Morningstar's fair value estimate.

Fair value

ADMA Biologics Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% premium over our quantitative fair value estimate of $13.05 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability weakens our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its sales yield of 17.4%, which ranks in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 15.5%, a core component of valuation, sits in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. While we believe the stock is overvalued, this underperformance had a positive impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ADMA Biologics discussion 0 comments

Add a comment